Biogen Hits Primary Endpoints in MS Study Motley Fool Biotech company Biogen Idec's (NASDAQ: BIIB ) developmental multiple sclerosis drug daclizumab succeeded in the SELECT phase 2b trial evaluating its safety and effectiveness in treating patients with relapse-remitting MS. The trial results, originally ... Biogen Idec Inc. (NASDAQ:BIIB) Jumps over 34% in 3 Months As Positive MS ... |
